Journals / Turkish Thoracic Journal / 2016 / Cilt: 17 - Sayı: 2

The Incidence and Related Risk Factors of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism

Pages
53–58
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

If probable risk factors are known, patients can be closely monitorized for CTEPH development

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: More than half of (> 50%) the patients with choronic thromboembolic pulmonary hypertension (CTEPH) have no acute pulmonary embolism history with clinical signs, so determining the actual incidence and prevalence of CTEPH is difficult.
📊
Key Findings & Data:Patients with pulmonary hypertension (PHT) (systolic PAB > 35 mmHg) determined by echocardiography performed in the 6th month were enrolled into the study.RESULTS: Fifty-seven of the 112 patients were female, and the mean age was 57.09 ± 17.30 years.
💡
Conclusion & Impact:If probable risk factors are known, patients can be closely monitorized for CTEPH development
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

OBJECTIVES: More than half of (> 50%) the patients with choronic thromboembolic pulmonary hypertension (CTEPH) have no acute pulmonary embolism history with clinical signs, so determining the actual incidence and prevalence of CTEPH is difficult. This study aimed to investigate the incidence of CTEPH and the risk factors that may be associated with CTEPH in patients with acute pulmonary thromboembolism (PTE).MATERIAL AND METHODS: Three hundred and eighteen patients with acute pulmonary embolism diagnosed by thorax CT or ventilation/perfussion scintigraphy in our clinic were included into this study. Patients with risk factors for pulmonary hypertension other than thromboembolic disease were excluded from the study. Patients with pulmonary hypertension (PHT) (systolic PAB > 35 mmHg) determined by echocardiography performed in the 6th month were enrolled into the study.RESULTS: Fifty-seven of the 112 patients were female, and the mean age was 57.09 ± 17.30 years. Presence of PHT was determined in the 6th month in 45 of the 112 patients (8 of them were symptomatic) and CTEPH incidence (symptomatic + asymptomatic) was identified as 40.16%. Symptomatic CTEPH incidence was calculated as 7.14%. When we searched about the risk factors that may have a role in the development of CTEPH; we determined that CTEPH risk was increased 4.59 times by only being male (95% CI 1.071-19.683, p= 0.040), 218 times by previous history of DVT (95% CI 1.235-38543.073, p= 0.041), and 56.903 times by PaO2 < 80 mmHg (95% CI 2.656-1219.228, p= 0.010).CONCLUSION: CTEPH development after PTE is a situation that can occur in many patients. If probable risk factors are known, patients can be closely monitorized for CTEPH development

🔖

Cite This Article

TOSUN, H., KIRKIL, G., DEVECİ, F., DAĞLI, N., ÖZCAN, M., TELO, S. (2016). The Incidence and Related Risk Factors of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. Turkish Thoracic Journal, Cilt: 17 - Sayı: 2, 53–58. https://ajindex.com/articles/418130

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Arseven O. Akut pulmonerembolizm. Ekim N, Türktaş H (editörler). Göğüs Hastalıkları Acilleri. Ankara: Bilimsel Tıp Yayınevi, 2000:247-65
  2. Metintaş M. Pulmoner tromboembolide akciğerde gelişen patofizyolojik değişiklikler. Metintaş M (editör). Pulmoner Tromboemboli. Eskişehir: ASD Toraks Yayınları, 2001:65-72
  3. Arseven O, Sevinç C, Alataş F, et al. Turkish Thoracic Society diagnosis and treatment report for pulmonary tromboembolism. TurkThoracic J 2009;10:1-49. [CrossRef] 4. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest 2006;129:192-7. [CrossRef] 5. Moser KM, Auger WR, Fedullo PF. Chronic major vessel thromboembolic pulmonary hypertension. Circulation 1990;81: 1735-43. [CrossRef] 6. Pengo V, Lensing A, Prins M, et al. Thromboembolic pulmonary hypertension study group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64. [CrossRef] 7. Wolf M, Boyer-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395-9
  4. Sompradeekul S, Fedullo PF, Le DT. Congenital and acquired thrombophilias in patients with chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 1999;159: 358-62
  5. Galie N, Hoeper MM, Humbert M, et al. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-37. [CrossRef] 10. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-78. [CrossRef] 11. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113:2011-20. [CrossRef] 12. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990;81: 1735-43. [CrossRef] 13. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465-72. [CrossRef] 14. Martí D, Gómez V, Escobar C, et al. Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension. Arch Broncopneumol 2010;46:628-33. [CrossRef] 15. Mi J, Sun ZH, Zhong MH, et al. Predictive f